Published in Mov Disord on July 01, 1995
Parry-Romberg syndrome with hemimasticatory spasm in pregnancy; A dystonia mimic. J Neurosci Rural Pract (2014) 0.81
Clinical Reasoning: a 57-year-old man with jaw spasms. Neurology (2013) 0.75
A case of painful hemimasticatory spasm with masseter muscle hypertrophy responsive to botulinum toxin. J Mov Disord (2009) 0.75
Hemimasticatory spasm: report of a case and review of the literature†. Tremor Other Hyperkinet Mov (N Y) (2014) 0.75
Commentary. J Neurosci Rural Pract (2014) 0.75
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation (2001) 2.82
Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study) BMJ (1996) 2.42
Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry (2002) 2.36
Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation (1997) 2.18
Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology (2005) 1.77
Juvenile asymmetric segmental spinal muscular atrophy (Hirayama's disease): three cases without evidence of "flexion myelopathy". Acta Neurol Scand (2001) 1.74
Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry (2000) 1.70
Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol (2012) 1.57
Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry (1999) 1.57
Phenotypic expression of the DYT1 mutation: a family with writer's cramp of juvenile onset. Ann Neurol (1998) 1.53
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol (2001) 1.52
The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol (2002) 1.51
Distal myasthenia gravis frequency and clinical course in a large prospective series. Acta Neurol Scand (2003) 1.50
Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology (2007) 1.48
Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation (1999) 1.46
Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology (2002) 1.46
Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology (2008) 1.45
Subcutaneous apomorphine in Parkinson's disease. Lancet (1988) 1.41
Early botulinum toxin treatment for spastic pes equinovarus--a randomized double-blind placebo-controlled study. Eur J Neurol (2014) 1.41
Transient restless legs syndrome after spinal anesthesia: a prospective study. Neurology (2002) 1.39
[Spinal fibrocartilaginous embolism]. Nervenarzt (2005) 1.39
[Vascular parkinsonian syndrome]. Nervenarzt (2006) 1.39
Cortical and brain stem hyperexcitability in striatonigral degeneration. Mov Disord (1998) 1.38
Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage (2000) 1.32
Influence of concurrent tasks on gait: a dual-task approach. Percept Mot Skills (1995) 1.31
The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur J Neurol (2012) 1.29
Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology (2003) 1.25
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry (1998) 1.25
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry (2004) 1.22
Levodopa in the treatment of Parkinson's disease. Eur J Neurol (2009) 1.21
Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (2004) 1.19
Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep (2002) 1.19
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry (1997) 1.17
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord (2000) 1.17
Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry (1996) 1.16
Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology (2011) 1.15
Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm (Vienna) (2002) 1.15
The natural course of Sneddon syndrome: clinical and magnetic resonance imaging findings in a prospective six year observation study. J Neurol Neurosurg Psychiatry (2003) 1.14
Comparative analysis of gait in Parkinson's disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy. Brain (1999) 1.14
Directional bias of initial visual exploration. A symptom of neglect in Parkinson's disease. Brain (1996) 1.13
Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur J Nucl Med (2000) 1.11
Clinical and polymyographic investigation of spasmodic torticollis. J Neurol (1992) 1.11
Temporal profile and cell subtype distribution of activated caspase-3 following experimental traumatic brain injury. J Neurochem (2000) 1.10
Replication of restless legs syndrome loci in three European populations. J Med Genet (2009) 1.08
Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol (1995) 1.08
Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia. Neurology (2006) 1.07
Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med (1997) 1.06
The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) (2005) 1.05
Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord (1997) 1.04
Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord (1999) 1.02
Clinical characteristics of the geste antagoniste in cervical dystonia. J Neurol (2001) 1.02
Trick maneuvers in cervical dystonia: investigation of movement- and touch-related changes in polymyographic activity. Mov Disord (1999) 1.02
How to diagnose MSA early: the role of magnetic resonance imaging. J Neural Transm (Vienna) (2005) 1.01
Magnetic resonance imaging in the diagnosis of spinal cord diseases. J Neurol Neurosurg Psychiatry (1985) 1.01
Orthostatic hypotension and attention in Parkinson's disease with and without dementia. J Neural Transm (Vienna) (2007) 1.00
Expression of Fas and Fas ligand after experimental traumatic brain injury in the rat. J Cereb Blood Flow Metab (2000) 1.00
Absence of disease related prion protein in neurodegenerative disorders presenting with Parkinson's syndrome. J Neurol Neurosurg Psychiatry (1994) 0.99
The rigid spine syndrome--a myopathy of uncertain nosological position. J Neurol Neurosurg Psychiatry (1985) 0.98
Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology (2000) 0.98
Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology (2000) 0.97
The prevalence of primary dystonia in the general community. Neurology (2002) 0.97
Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol (2009) 0.95
Progressive multifocal leukoencephalopathy presenting with an isolated focal movement disorder. Mov Disord (2000) 0.95
Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord (1999) 0.94
Premorbid personality of Parkinson patients. J Neural Transm Suppl (1983) 0.94
Charcot-Marie-Tooth neuropathy type 2 and P0 point mutations: two novel amino acid substitutions (Asp61Gly; Tyr119Cys) and a possible "hotspot" on Thr124Met. Brain Pathol (2000) 0.94
Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm (Vienna) (2013) 0.93
Prevalence of primary headaches and cranial neuralgias in men and women aged 55-94 years (Bruneck Study). Cephalalgia (2008) 0.92
Dose standardization of botulinum toxin. Mov Disord (1998) 0.92
Increased expression of apolipoprotein D following experimental traumatic brain injury. J Neurochem (1999) 0.91
Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res (2001) 0.91
Validation of a mail questionnaire for parkinsonism in two languages (German and Italian). J Neurol (1999) 0.90
Interference of rhythmic constraint on gait in healthy subjects and patients with early Parkinson's disease: evidence for impaired locomotor pattern generation in early Parkinson's disease. Mov Disord (1999) 0.90
Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord (2001) 0.89
Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord (1999) 0.89
High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol (1991) 0.89
Depression in Parkinson's disease. An update. Adv Neurol (2001) 0.89
The auditory startle reaction in parkinsonian disorders. Mov Disord (2001) 0.88
Reversible severe myopathy of respiratory muscles due to adult-onset type III glycogenosis. Neuromuscul Disord (1999) 0.88
Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience (2000) 0.88
Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. J Neural Transm (Vienna) (2004) 0.88
Quantification of sensory trick impact on tremor amplitude and frequency in 60 patients with head tremor. Mov Disord (2000) 0.87
Dystonia in ataxia telangiectasia: report of a case with putaminal lesions and decreased striatal [123I]iodobenzamide binding. Mov Disord (1994) 0.87